Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of cinnamaldehyde in preparation of drugs for targeted therapy of drug-resistant aspergillus infection

A technology of drug aspergillus and targeted therapy, applied in the field of medicine, can solve problems such as poor prognosis and difficult clinical treatment

Active Publication Date: 2017-01-25
THE SECOND HOSPITAL OF HEBEI MEDICAL UNIV
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although the above-mentioned drugs have certain antibacterial effects, due to the increasing number of drug-resistant strains in recent years, especially resistant to azole drugs, such as fluconazole, itraconazole, voriconazole, ketoconazole, flucytosine, etc., Clinical treatment is still difficult and the prognosis is poor

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of cinnamaldehyde in preparation of drugs for targeted therapy of drug-resistant aspergillus infection
  • Application of cinnamaldehyde in preparation of drugs for targeted therapy of drug-resistant aspergillus infection
  • Application of cinnamaldehyde in preparation of drugs for targeted therapy of drug-resistant aspergillus infection

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0030] Embodiment 1 removes patchouli ketone for comparative example 1, and others remain unchanged.

[0031] The tested invasive and drug-resistant Aspergillus strains came from the Mycology Department of the Second Hospital of Hebei Medical University. Direct microscopic examination of sputum specimens showed a large number of thick mycelium separated by branches at 45 degrees. , after identification and drug susceptibility test as invasive drug-resistant Aspergillus fumigatus and Aspergillus flavus, the results are shown in Table 1.

[0032] Table 1 Antifungal drugs against invasive drug-resistant Aspergillus MIC mgml -1 value

[0033] Invasive resistant Aspergillus strains n Fluconazole Itraconazole Amphotericin B Voriconazole Ketoconazole Flucytosine Aspergillus fumigatus 30 16-64 8-16 1-8 1-4 64 64 Aspergillus flavus 30 8-32 4-16 8-32 4-16 64 64

[0034] According to the method described in Experimental Example 1 discl...

Embodiment 2

[0038] In order to further develop the clinical effect of cinnamaldehyde used alone, the present invention proposes to include cinnamic aldehyde with hydroxypropyl-β-cyclodextrin to obtain cinnamic aldehyde monomer clathrate. The cinnamon aldehyde monomer clathrate can be further prepared into oral and injection dosage forms through conventional techniques in the field of pharmaceutical technology. The cinnamon aldehyde monomer clathrate is prepared from the following components in parts by weight: 10-60 cinnamaldehyde and 20-80 hydroxypropyl-β-cyclodextrin. The hydroxypropyl-β-cyclodextrin is 2-hydroxypropyl-β-cyclodextrin. Embodiment 2 cinnamic aldehyde monomer clathrate of the present invention

[0039] Composition: Cinnamaldehyde 1.25g (50 parts by weight)

[0040] 2-hydroxypropyl-β-cyclodextrin 1.25g (50 parts by weight)

[0041] Preparation:

[0042] 1) Add 2-hydroxypropyl-β-cyclodextrin to 80°C deionized distilled water, stir to dissolve, then cool down to 20°C to p...

Embodiment 3

[0044] 3) Filter the refrigerated liquid obtained in step 2), wash the solid matter with a small amount of distilled water, dry it in vacuum at a low temperature of 5°C for 24 hours, grind it, sieve it through 80 mesh, wash it with ethyl acetate three times, and dry it in the air to obtain white Loose cinnamaldehyde monomer inclusion compound. Embodiment 3 cinnamic aldehyde monomer clathrate of the present invention

[0045] Composition: Cinnamaldehyde 1g (10 parts by weight)

[0046] 2-hydroxypropyl-β-cyclodextrin 2g (20 parts by weight)

[0047] Preparation method: with embodiment 2.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to application of cinnamaldehyde in preparation of drugs for targeted therapy of drug-resistant aspergillus infection, and belongs to the technical field of medicines. Drug-resistant aspergillus is invasive and disseminative drug-resistant aspergillus such as aspergillus fumigatus and aspergillus flavus. A cinnamaldehyde preparation is developed by methods of tissue mycology, tissue pathology, tissue biochemistry and tissue electron microscopy. An efficient, low-toxicity and novel antibacterial agent which is used for targeted therapy of drug-resistant aspergillus infection is provided for fungal infection of departments such as a clinical pneumology department, a hematology department, an emergency treatment ICU, an oncology department and organ grafting, in-vivo pharmacodynamics, an action mechanism and a theoretical experiment basis are provided for research and development of traditional Chinese medicines for treating invasive and disseminative drug-resistant aspergillus infection, and conditions are created for transformation of scientific achievements.

Description

technical field [0001] The invention relates to the application of an active ingredient in the preparation of medicines, more specifically, to the application of cinnamaldehyde in the preparation of medicines for targeted treatment of drug-resistant Aspergillus infection, and belongs to the technical field of medicine. Background technique [0002] Invasive drug-resistant fungal infection refers to fungal invasion of human tissues and blood, where they grow and reproduce, causing tissue damage, organ dysfunction, pathological changes and pathophysiological processes of inflammatory response. In recent years, with the continuous promotion and development of organ transplantation and various catheter technologies, the irrational use of antibiotics, and the number of critically ill patients treated with ventilator-assisted ventilation and parenteral nutrition support, the number of critically ill patients has continued to increase, coupled with changes in the spectrum of human d...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/11A61K47/69A61K47/26A61P31/10
CPCA61K31/11A61K47/26
Inventor 王刚生邓洁华李继红张朝军赵宜乐
Owner THE SECOND HOSPITAL OF HEBEI MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com